Showing 1 – 1 of 1 results.
Curated
Restricted
Advancing Virtual Reality-Based Attentional Bias as a Biomarker for Tobacco Use Disorder, San Diego, California, 2024-2025 (ICPSR 39816)
Released/updated on: 2026-04-13
Geographic coverage: San Diego, United States, California
Time period: 2024-11-20--2025-03-03
The Varenicline Virtual Reality Study includes daily cigarette users, ages 22+, from the San Diego community. Participants are assessed on the VR Nicotine Cue Exposure paradigm then pseudo-randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (target n per group=100; target total N=200). Following eight days of titration, participants are assessed again on the VR Nicotine Cue Exposure paradigm.